Blockchain Registration Transaction Record

Onco-Innovations Targets Cancer Resistance with Novel PNKP Inhibitor

Onco-Innovations advances ONC010, a PNKP inhibitor for DNA repair in cancer, backed by patents and AI platform SynoGraph. Learn about this emerging DDR therapy leader.

This news matters because Onco-Innovations is developing a potential new class of cancer therapies that could overcome treatment resistance, a major hurdle in oncology. By targeting DNA repair pathways with its PNKP inhibitor ONC010, the company addresses a critical unmet need for patients who relapse after standard treatments like PARP inhibitors. The integration of AI through SynoGraph™ further personalizes therapy, improving clinical trial success rates and patient outcomes. For investors, Onco-Innovations represents a high-potential opportunity in the DDR space, backed by a strong patent portfolio and strategic advancements toward clinical trials.